Uveitis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Uveitis – Pipeline Review, H2 2019’, provides an overview of the Uveitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Uveitis

– The report reviews pipeline therapeutics for Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Uveitis therapeutics and enlists all their major and minor projects

– The report assesses Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Uveitis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Uveitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Aciont Inc

Akari Therapeutics Plc

Aldeyra Therapeutics Inc

Alvotech ehf

Apidel SA

Apitope International NV

Bonac Corp

Bristol-Myers Squibb Co

Chugai Pharmaceutical Co Ltd

Dobecure SL

E&B Technologies LLC

Elasmogen Ltd

Eleusis Ltd

Eli Lilly and Co

Emerald Bioscience Inc

EnhanX Biopharm Inc

Enzo Biochem Inc

EyePoint Pharmaceuticals Inc

Eyevensys SAS

EyGen Ltd

F. Hoffmann-La Roche Ltd

Galapagos NV

HanAll Biopharma Co Ltd

HanAll Biopharma Co Ltd

Idogen AB

InSight Biopharmaceuticals Ltd

IVERIC bio Inc

Kodiak Sciences Inc

Kv1.3 Therapeutics

MetrioPharm AG

Mitotech SA

Naegis Pharmaceuticals Inc

NeuClone Pty Ltd

Novaliq GmbH

Novartis AG

Oculis SA

OKYO Pharma Ltd

OncoNOx ApS

Orchid Pharma Ltd

OSE Immunotherapeutics

Palatin Technologies Inc

Panag Pharma Inc

Panoptes Pharma GesmbH

Pfizer Inc

Pharmapraxis

Re-Pharm Ltd

RiniSight Inc

Santen Pharmaceutical Co Ltd

SFA Therapeutics LLC

Siam Bioscience Co Ltd

Tarsius Pharma Ltd

Tianjin Pharmaceuticals Group Co Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Uveitis Overview 6

Uveitis Therapeutics Development 7

Uveitis Therapeutics Assessment 17

Uveitis Companies Involved in Therapeutics Development 25

Uveitis Drug Profiles 40

Uveitis Dormant Projects 177

Uveitis Discontinued Products 181

Uveitis Product Development Milestones 182

Appendix 200

List of Tables

“List of Tables

Number of Products under Development for Uveitis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Uveitis – Pipeline by Aciont Inc, H2 2019

Uveitis – Pipeline by Akari Therapeutics Plc, H2 2019

Uveitis – Pipeline by Aldeyra Therapeutics Inc, H2 2019

Uveitis – Pipeline by Alvotech ehf, H2 2019

Uveitis – Pipeline by Apidel SA, H2 2019

Uveitis – Pipeline by Apitope International NV, H2 2019

Uveitis – Pipeline by Bonac Corp, H2 2019

Uveitis – Pipeline by Bristol-Myers Squibb Co, H2 2019

Uveitis – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019

Uveitis – Pipeline by Dobecure SL, H2 2019

Uveitis – Pipeline by E&B Technologies LLC, H2 2019

Uveitis – Pipeline by Elasmogen Ltd, H2 2019

Uveitis – Pipeline by Eleusis Ltd, H2 2019

Uveitis – Pipeline by Eli Lilly and Co, H2 2019

Uveitis – Pipeline by Emerald Bioscience Inc, H2 2019

Uveitis – Pipeline by EnhanX Biopharm Inc, H2 2019

Uveitis – Pipeline by Enzo Biochem Inc, H2 2019

Uveitis – Pipeline by EyePoint Pharmaceuticals Inc, H2 2019

Uveitis – Pipeline by Eyevensys SAS, H2 2019

Uveitis – Pipeline by EyGen Ltd, H2 2019

Uveitis – Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Uveitis – Pipeline by Galapagos NV, H2 2019

Uveitis – Pipeline by HanAll Biopharma Co Ltd, H2 2019

Uveitis – Pipeline by HanAll Biopharma Co Ltd, H2 2019

Uveitis – Pipeline by Idogen AB, H2 2019

Uveitis – Pipeline by InSight Biopharmaceuticals Ltd, H2 2019

Uveitis – Pipeline by IVERIC bio Inc, H2 2019

Uveitis – Pipeline by Kodiak Sciences Inc, H2 2019

Uveitis – Pipeline by Kv1.3 Therapeutics, H2 2019

Uveitis – Pipeline by MetrioPharm AG, H2 2019

Uveitis – Pipeline by Mitotech SA, H2 2019

Uveitis – Pipeline by Naegis Pharmaceuticals Inc, H2 2019

Uveitis – Pipeline by NeuClone Pty Ltd, H2 2019

Uveitis – Pipeline by Novaliq GmbH, H2 2019

Uveitis – Pipeline by Novartis AG, H2 2019

Uveitis – Pipeline by Oculis SA, H2 2019

Uveitis – Pipeline by OKYO Pharma Ltd, H2 2019

Uveitis – Pipeline by OncoNOx ApS, H2 2019

Uveitis – Pipeline by Orchid Pharma Ltd, H2 2019

Uveitis – Pipeline by OSE Immunotherapeutics, H2 2019

Uveitis – Pipeline by Palatin Technologies Inc, H2 2019

Uveitis – Pipeline by Panag Pharma Inc, H2 2019

Uveitis – Pipeline by Panoptes Pharma GesmbH, H2 2019

Uveitis – Pipeline by Pfizer Inc, H2 2019

Uveitis – Pipeline by Pharmapraxis, H2 2019

Uveitis – Pipeline by Re-Pharm Ltd, H2 2019

Uveitis – Pipeline by RiniSight Inc, H2 2019

Uveitis – Pipeline by Santen Pharmaceutical Co Ltd, H2 2019

Uveitis – Pipeline by SFA Therapeutics LLC, H2 2019

Uveitis – Pipeline by Siam Bioscience Co Ltd, H2 2019

Uveitis – Pipeline by Tarsius Pharma Ltd, H2 2019

Uveitis – Pipeline by Tianjin Pharmaceuticals Group Co Ltd, H2 2019

Uveitis – Dormant Projects, H2 2019

Uveitis – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Uveitis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared